Our new Longevity Biotech Report puts a number on longevity’s payoff – and asks who actually gets to cash it in.
With thanks to MuseCell Innovations, sponsor of the Longevity Biotech Report.
Put a number like 100x next to the word “return” and most readers will assume someone, somewhere, is about to get rich. That is not quite what is happening here.
The claim comes from Longevity.Technology’s new Longevity Biotech Report, and it runs like this: slow aging enough to add ten years to US life expectancy, and the resulting gain to the American economy would be worth $366.8 trillion [1]. Spend a decade building and buying the therapies required to get there, at the market size the report itself projects, and the bill comes to around $3.3 trillion. Divide one by the other. The multiple survives.
Longevity.Technology: A hundredfold return sounds like the sort of thing a venture capitalist scribbles on a napkin before ordering champagne, and there is a genuine risk that the figure gets read that way – as a return an investor might personally pocket. It is not that. Nobody collects a check for $366.8 trillion; instead, the sum represents value distributed across an entire economy, not profit accruing to a biotech portfolio. Understanding that distinction matters more than admiring the number itself.
Two ways to cut the number
The underlying study, led by economists Andrew Scott and Martin Ellison alongside biologist David Sinclair and published in Nature Aging, puts the value of those additional ten years at $366.8 trillion in total, or $7.2 trillion annually at a 2% discount rate – equivalent, notably, to roughly a third of 2019 US GDP. Set against that is the report’s own estimate of US market size: around $330 billion a year by 2045, assuming gerotherapeutics reach patients from 2035 onward, priced comparably to today’s GLP-1 drugs, and taken up by 35% of the eligible over-45 population.
Run those figures annually and the ratio comes out at roughly 22x. Run them across a decade of accumulated spending against the full valuation, and it climbs toward 100x. Same underlying data; different lens. Neither figure is wrong. They simply answer slightly different questions.
Value to society not to shareholders
Here is the part worth sitting with. The $330 billion is what flows through the market – toward biotech companies, their investors, the whole commercial apparatus of drug development and delivery. The $7.2 trillion is something else entirely: a diffuse gain spread across a longer-working population, a healthcare system relieved of some of its costliest late-life burdens, an economy that simply produces more because fewer of its people are sidelined by age-related decline. Nobody writes a single invoice for that. It arrives in tax receipts, in productivity, in years that would otherwise have been lost to frailty – slowly, and to nobody in particular.
That gap between private capture and public benefit is not a flaw in the model. It is the argument. Markets are notoriously poor at pricing diffuse, long-horizon goods – prevention chief among them – which is precisely why so much of the most valuable healthcare intervention available to a society tends to be chronically underfunded relative to what it is actually worth. A hundredfold societal return sitting mostly outside anyone’s balance sheet is not proof that the case is weak. It is closer to an explanation of why the case has gone unmade for so long.
Why the number still needs care
The figure is American, not global, and it inherits every assumption baked into the report’s own $617 billion TAM: a 2035 first approval, GLP-1-level pricing, that 35% ceiling on uptake. Move any of those sliders and the multiple moves with them. This is not a second, independently verified number; it is the same model, viewed from a different angle, wearing a more startling label.
The Explorer behind that model lets you move those same sliders yourself. Push uptake down, pull approval further out, price the intervention differently, and the multiple resets to whatever your own view of the market can defend – try it HERE.
The ledger nobody is keeping
What the exercise offers is not certainty but a shape – a rough sketch of where the incentives fail to line up with the value at stake. Whether anyone acts on that gap, long before the arithmetic settles into something more precise, remains the more interesting question.
The full Longevity Biotech Report – arithmetic, assumptions and all – remains free to download here.
